Phase 3 OCEANIC-STROKE trial shows asundexian cut recurrent ischemic stroke
Phase 3 OCEANIC-STROKE data showed asundexian plus antiplatelet therapy reduced recurrent ischemic stroke versus placebo. Major bleeding rates were similar between groups.
Recurrent Ischemic Stroke
DiseaseRelated News
Factor XIa Inhibitor Reduces Stroke Recurrence Without Increasing Bleeding Risk in Phase 3 Trial
The phase 3 OCEANIC-STROKE trial of 12,327 patients showed asundexian, an oral Factor XIa inhibitor, reduced ischemic stroke recurrence by 26% when added to standard antiplatelet therapy, with no increase in major bleeding events.